ADVB

Advanced Biomed Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
GlobeNewsWire
1 month ago
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Neutral
TheNewswire
6 months ago
Sonoro Energy, Advanced BioCatalytics, and NexTier Energy Launch Strategic Collaboration to Advance Heavy Oil Recovery from Carbonate Reservoirs in the Middle East
May 5, 2025 – TheNewswire - Calgary, Alberta – Sonoro Energy Ltd. (“Sonoro” or the “Company” (TSX Venture: SNV) is pleased to announce that Sonoro, Advanced BioCatalytics Corporation, and NexTier Energy LLC have developed a strategic collaboration focused on enhancing heavy oil production from carbonate reservoirs in the Middle East through the application of cutting-edge enhanced oil recovery (EOR) technologies. The partnership leverages the complementary strengths of each company—biotechnology innovation, reservoir engineering expertise, and regional energy leadership—to address one of the more technically challenging resource opportunities in the global energy sector
Sonoro Energy, Advanced BioCatalytics, and NexTier Energy Launch Strategic Collaboration to Advance Heavy Oil Recovery from Carbonate Reservoirs in the Middle East
Neutral
GlobeNewsWire
8 months ago
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The Shares began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol “ADVB.”
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering